Ang-(1-7), ACE2 and Cardiac Function
Ang-(1-7)、ACE2 与心脏功能
基本信息
- 批准号:7386015
- 负责人:
- 金额:$ 33.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-01 至 2009-03-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdenovirus VectorAffinityAngiotensin IAngiotensin IIAngiotensin II ReceptorAngiotensin ReceptorAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAntisense OligonucleotidesAntisense TechnologyBackBindingBiochemicalBiologicalBlood CirculationBlood PressureBreedingCarboxypeptidaseCardiacCardiovascular systemChemicalsChromosome MappingCloningCollagenComparative StudyCompatibleConditionConsciousCoupledDataDevelopmentEnzymesExperimental ModelsFeedbackFibrosisFluid BalanceGene ExpressionGenesGenetic ModelsGrowthGrowth FactorHeartHeart HypertrophyHeart RateHomologous GeneHypertensionInvestigationKnockout MiceLaboratoriesLinkLisinoprilMeasuresMediatingMessenger RNAMicrodialysisModelingMolecularMusMyocardialMyocardiumNatriuretic AgentsNeprilysinOrphanPeptidyl-Dipeptidase APerformancePhysiologyPlayProductionQuantitative Trait LociRateRattusReceptor SignalingRegulationRelative (related person)Renal functionRenin-Angiotensin SystemReportingResearchRoleStimulusStructureSystemTestingTissuesTransgenic ModelTransgenic OrganismsUpper armVasoconstrictor AgentsVasodilator AgentsWestern Blottingangiotensin I (1-7)blood pressure regulationconceptcongenicenzyme activitygenetic linkage analysisimmunocytochemistryin vivoinhibitor/antagonistinstrumentmetaplastic cell transformationnormotensiveprolinalprolyl oligopeptidasereceptorresearch study
项目摘要
The vasodilator and antihypertensive effects of the heptapeptide angiotensin-(1-7) [Ang-(1-7)] promoted a more intense investigation of the biochemical physiology of the renin angiotensin system (RAS) and was a stimulus in the recent discovery of an angiotensin converting enzyme (ACE) homolog (ACE2) which acting as a carboxypeptidase, converts angiotensin II (Ang II) into Ang-(1-7), is insensitive to ACE inhibitors, is linked to the expression of several genetics models of hypertension and regulates cardiac function. The primary objective of this proposal will be to show that ACE2 expression and activity plays a critical role in determining the opposing actions of Ang-(1-7) on Ang II in terms of ventrieular contractility and the development of hypertension-related cardiac hypertrophy. These studies will be performed in normotensive
Lewis and mRen2.Lewis hypertensive rats. To accomplish these objectives we will: 1)- determine the expression and tissue localization of Ang-(1-7) and ACE2 in the hearts of onrmotensive Lewis and mRen2.Lewis hypertensive rats alone and in relation to the supporting collagen matrix and angiotensin receptors (Specific Aim 1); 2)- characterize the role of cardiac ACE2 and other Ang-(1-7) forming enzymes in contributing to the formation of Ang-(1-7) in the heart versus the systemic circulation (Specific Aim 2); 3) assess the effects of chemical inhibition of ACE2 on the regulation of blood pressure and cardiac function in chronically instrumented normotensive and mRen2.Lewis hypertensive rats (Specific Aim 3); and 4)- employ
antisense technology and an adenovirus vector to either inhibit or selectively augment, respectively, the expression of cardiac ACE2 in normotensive Lewis and mRen2.Lewis hypertensive rats to study the effects of these maneuvers on cardiac performance in isolated heart per fusion model (Specific Aim 4). The proposed studies will provide a new understanding of the biochemical physiology of the RAS and the mode of action of therapies that depend upon inhibition of either ACE or Ang II receptor blockade.
七肽血管紧张素-(1-7)[Ang-(1 - 7)]的血管扩张和抗高血压作用促进了对肾素血管紧张素系统(RAS)的生化生理学的更深入的研究,并且是最近发现的血管紧张素转换酶(ACE)同系物(ACE 2)的刺激因素,ACE 2作为羧肽酶起作用,将血管紧张素II(Ang II)转化为Ang-(1-7),对ACE抑制剂不敏感,与几种高血压遗传模型的表达相关,并调节心脏功能。本研究的主要目的是证明ACE 2的表达和活性在决定Ang-(1-7)对Ang II在心室收缩性和高血压相关性心肌肥大的发展方面的相反作用中起关键作用。这些研究将在血压正常的
刘易斯和mRen 2.刘易斯高血压大鼠。为了实现这些目标,我们将:1)确定Ang-(1-7)和ACE 2在非高血压刘易斯和mRen 2大鼠心脏中的表达和组织定位。刘易斯高血压大鼠单独和与支持胶原基质和血管紧张素受体相关(具体目标1); 2)-表征心脏ACE 2和其他Ang-(1-7)形成酶在促进Ang-(1-7)形成中的作用3)评估ACE 2的化学抑制对慢性仪器正常血压大鼠和mRen2.Lewis高血压大鼠中血压和心脏功能调节的影响(具体目的3);和4)采用
反义技术和腺病毒载体分别抑制或选择性增加正常血压刘易斯和mRen 2.刘易斯高血压大鼠中心脏ACE 2的表达,以研究这些操作对分离的心脏灌注模型中心脏性能的影响(具体目标4)。拟议的研究将提供一个新的理解的生化生理学的RAS和治疗的作用方式,依赖于抑制ACE或血管紧张素II受体阻滞剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CARLOS M FERRARIO其他文献
CARLOS M FERRARIO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CARLOS M FERRARIO', 18)}}的其他基金
Angiotensin (1-12) and Hypertension in the Elderly
血管紧张素 (1-12) 与老年人高血压
- 批准号:
10370035 - 财政年份:2021
- 资助金额:
$ 33.72万 - 项目类别:
Angiotensin (1-12) and Hypertension in the Elderly
血管紧张素 (1-12) 与老年人高血压
- 批准号:
10495233 - 财政年份:2021
- 资助金额:
$ 33.72万 - 项目类别:
Angiotensin-(1 -12). Novel Pathways for Angiotensin Peptide Formation
血管紧张素-(1 -12)。
- 批准号:
8250036 - 财政年份:2011
- 资助金额:
$ 33.72万 - 项目类别:
Angiotensin-(1 -12). Novel Pathways for Angiotensin Peptide Formation
血管紧张素-(1 -12)。
- 批准号:
8147911 - 财政年份:2010
- 资助金额:
$ 33.72万 - 项目类别:
Angiotensin-(1-7). Novel Pathways for Angiotensin Peptide Formation
血管紧张素-(1-7)。
- 批准号:
7647683 - 财政年份:2009
- 资助金额:
$ 33.72万 - 项目类别:
相似海外基金
Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
- 批准号:
19K09482 - 财政年份:2019
- 资助金额:
$ 33.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
- 批准号:
2273599 - 财政年份:2019
- 资助金额:
$ 33.72万 - 项目类别:
Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
- 批准号:
18K14964 - 财政年份:2018
- 资助金额:
$ 33.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
- 批准号:
16K18873 - 财政年份:2016
- 资助金额:
$ 33.72万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
- 批准号:
9193681 - 财政年份:2016
- 资助金额:
$ 33.72万 - 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
- 批准号:
15K18939 - 财政年份:2015
- 资助金额:
$ 33.72万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
- 批准号:
26450450 - 财政年份:2014
- 资助金额:
$ 33.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
- 批准号:
26462183 - 财政年份:2014
- 资助金额:
$ 33.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
- 批准号:
26893253 - 财政年份:2014
- 资助金额:
$ 33.72万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
- 批准号:
24701021 - 财政年份:2012
- 资助金额:
$ 33.72万 - 项目类别:
Grant-in-Aid for Young Scientists (B)














{{item.name}}会员




